Micardis 80mg gains indication for cardiovascular risk reduction

The FDA has approved Micardis 80mg (telmisartan tablets, from Boehringer Ingelheim), an angiotensin II receptor blocker (ARB), for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients ≥55 years of age at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme inhibitors (ACE inhibitors). This approval was based on data from a clinical trial involving more than 31,000 high-risk cardiovascular patients with normal blood pressure or treated high blood pressure with a history of a broad range of cardiovascular diseases. Results of these studies support that Micardis 80mg is more effective than placebo.

Micardis is already indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

For more information call (800) 243-0127 or visit www.micardis.com.